Literature DB >> 18587015

Epigenetic dysregulation of the DAP kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in acute leukaemias.

C S Chim1, W W L Chan, Y L Kwong.   

Abstract

BACKGROUND: Dysregulation of apoptosis is important in carcinogenesis. AIM AND METHODS: To analyse the potential inactivation of the DAP kinase/p14/HDM2/p53/Apaf-1 pathway by aberrant promoter methylation in acute leukaemias.
RESULTS: Of five leukaemic lines examined, p14 was unmethylated in Raji, HL60 and U937, but completely deleted in Jurkat and NB4. DAP kinase was totally methylated in Raji and NB4, but unmethylated in HL60, Jurkat and U937. Apaf-1 was unmethylated in all the lines. At diagnosis, DAP kinase methylation occurred in eight (25%) APL patients and none of the other AML patients (8/32 vs 0/50, p = 0.001). DAP kinase methylation was detected in four (16%) ALL patients. p14 and Apaf-1 methylation was not detected in any of the 32 cases of acute promyelocytic leukaemia (APL), 50 cases of other subtypes of acute myeloid leukaemia (AML), and 25 cases of acute lymphoblastic leukaemia.
CONCLUSION: Among AML subtypes, DAP kinase is preferentially hypermethylated in APL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18587015     DOI: 10.1136/jcp.2007.047324

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  5 in total

Review 1.  Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.

Authors:  Kumudha Balakrishnan; Varsha Gandhi
Journal:  Expert Opin Investig Drugs       Date:  2012-03-09       Impact factor: 6.206

Review 2.  Promoter hypermethylation in prostate cancer.

Authors:  Jong Y Park
Journal:  Cancer Control       Date:  2010-10       Impact factor: 3.302

3.  DNA methylation in promoter region as biomarkers in prostate cancer.

Authors:  Mihi Yang; Jong Y Park
Journal:  Methods Mol Biol       Date:  2012

4.  Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients.

Authors:  Chor Sang Chim
Journal:  J Transl Med       Date:  2010-11-26       Impact factor: 5.531

5.  Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in acute lymphoblastic leukemia.

Authors:  Amaia Vilas-Zornoza; Xabier Agirre; Vanesa Martín-Palanco; José Ignacio Martín-Subero; Edurne San José-Eneriz; Leire Garate; Sara Álvarez; Estíbaliz Miranda; Paula Rodríguez-Otero; José Rifón; Antonio Torres; María José Calasanz; Juan Cruz Cigudosa; José Román-Gómez; Felipe Prósper
Journal:  PLoS One       Date:  2011-02-28       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.